Your Followed Topics

Top 8 u.s. securities and exchange commission News Today

#1
SEC's ex-enforcement chief clashed with bosses before leaving, Reuters sources say
#1 out of 8
business1d ago

SEC's ex-enforcement chief clashed with bosses before leaving, Reuters sources say

https://www.cnbc.com/2026/03/23/secs-ex-enforcement-chief-clashed-with-bosses-before-leaving.html
Cnbc.com
  • Ryan resigned after just over six months as SEC enforcement chief, per Reuters sources.
  • She clashed with agency leaders over enforcement direction, including cases tied to Trump circles, according to three people familiar with the matter.
  • Tensions also involved how crypto cases and executive actions were handled under Atkins’ leadership.
  • The report notes a shift away from large corporate cases toward fraud and manipulation cases like Ponzi schemes.
  • Sources described Ryan as an unusual pick for leading the enforcement team of over 1,000 people.
  • Reports said Ryan backed staff in disputes with individuals and companies under investigation.
  • A February speech cited fixing aspects of the enforcement program while affirming commitment to quality actions.
  • The Sun settlement and Musk case were cited as examples of enforcement activity entwined with political context.
  • Ryan’s leadership faced pushback on how to handle cases touching major political donors and figures.
  • SEC chair Paul Atkins and other Republican appointees reportedly resisted Ryan's aggressive stance.
Vote 0
0
#2
Achieve Life Sciences 2025 10-K: Net loss $54.6M, EPS $(1.25)
#2 out of 8
business1d ago

Achieve Life Sciences 2025 10-K: Net loss $54.6M, EPS $(1.25)

https://www.tradingview.com/news/tradingview:1759135117419:0-achieve-life-sciences-2025-10-k-net-loss-54-6m-eps-1-25/
Tradingview.com
  • Achieve Life Sciences reports a 2025 net loss of $54.6 million and a per-share loss of $1.25.
  • Cash holdings at year end totaled $36.4 million, with ongoing concerns about the company’s ability to continue as a going concern.
  • A June 20, 2026 PDUFA date was set for the NDA of cytisinicline for smoking cessation.
  • Breakthrough Therapy designation and CNPV support FDA engagement for faster review.
  • U.S. manufacturing partnership with Adare and technology transfer underway for a 2027 US launch.
  • ORCA-OL trial completed in September 2025; safety and efficacy data continue to support regulatory progress.
  • 2025 operating spend increased to support anticipated commercialization activities.
  • NDA for cytisinicline advanced as regulatory momentum grows for smoking cessation and vaping indications.
  • No revenue figure disclosed for 2025 in the 10-K filing.
  • Company disclosed substantial doubt about continuing as a going concern.
Vote 0
0
#3
Hour Loop 10-K: $142.4M Revenue, Net Income $1.7M
#3 out of 8
business1d ago

Hour Loop 10-K: $142.4M Revenue, Net Income $1.7M

https://www.tradingview.com/news/tradingview:5822cf0842004:0-hour-loop-10-k-142-4m-revenue-net-income-1-7m/
Tradingview.com
  • Hour Loop reports 2025 total revenues of $142.44 million, up 3.03% year over year, driven by a 3.95% rise in order volume.
  • Net income rose to $1.70 million in 2025 from $0.66 million, aided by improved operating efficiency.
  • Gross profit reached $74.63 million with a modest margin improvement versus the prior year.
  • Operating income rose to $2.46 million due to improved operating efficiency.
  • Tax expense increased year over year, impacting the bottom line.
  • About 98% of Hour Loop's sales come via Amazon, with Walmart and the company site negligible.
  • Hour Loop manages over 100,000 SKUs across home, toys, kitchen, apparel and electronics.
  • The company intends to rapidly scale managers, vendors and SKUs to grow its e-commerce presence.
  • The information is based on Hour Loop's SEC filing and an AI-powered TradingView summary.
  • TradingView provides latest news coverage referencing Hour Loop's 2025 financials.
Vote 0
0
#4
finance.yahoo.com
#4 out of 8
business20h ago

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

https://finance.yahoo.com/markets/stocks/articles/tarsus-pharma-stock-20-insider-172600478.html
Finance.yahoo.com
  • Tarsus Pharmaceuticals confirms a significant RSU-related sale by its Chief HR Officer in mid-March 2026, totaling about $839,000.
  • The sale used a mandatory sell-to-cover structure tied to RSU vesting, signaling tax mechanics rather than a strategic stock bet.
  • Post-trade, Whitfield’s direct holdings stood at 35,028 shares, valued around $2.34 million at the time.
  • The sale represented about 25.95% of Whitfield’s direct holdings, reducing exposure in the near term.
  • No indirect entities or derivatives were involved in the sale, per the Form 4 filing.
  • The weighted average sale price was about $68.36 per share, with the market close near $66.75 on trade day.
  • Tarsus Pharmaceuticals highlighted strong 2025 sales and cash runway amid ongoing pipeline catalysts.
  • The FT Motley Fool piece notes management intends to advance TP-03 and other pipeline assets with Phase 2 catalysts.
  • Analysts caution the insider sale may not reflect broader company sentiment toward fundamentals.
  • The stock's performance context shows a 22.48% total return over the past year as of the transaction date.
Vote 0
0
#5
Arxis, Mission-Critical Components Manufacturer, Files for Nasdaq IPO
#5 out of 8
business16h ago

Arxis, Mission-Critical Components Manufacturer, Files for Nasdaq IPO

https://www.tradingview.com/news/tradingview:6baef06843459:0-arxis-mission-critical-components-manufacturer-files-for-nasdaq-ipo/
Tradingview.com
  • Arxis files for Nasdaq IPO under ticker ARXS to go public on the Nasdaq Global Select Market.
  • Proceeds aim to repay borrowings and fund general corporate purposes.
  • Arcline will retain voting control through high-vote shares after the IPO.
  • Arxis designs and manufactures components for defense, space, aerospace, and industrial markets.
  • The company operates in two segments and serves defense & space, commercial aerospace, and industrial technology.
  • In 2025, defense & space accounted for about 47% of revenue.
  • Arxis has 5,000+ customers and 72 manufacturing facilities worldwide.
  • Arxis boasts 67 foundational proprietary technologies and 600+ embedded platforms.
  • Arxis plans to use IPO proceeds for working capital and potential acquisitions.
  • The IPO is led by Goldman Sachs, Morgan Stanley, and Jefferies.
Vote 0
0
#6
CEA Industries says YZi Labs' request to fix record date is deficient, blocks consent solicitation
#6 out of 8
business16h ago

CEA Industries says YZi Labs' request to fix record date is deficient, blocks consent solicitation

https://www.tradingview.com/news/tradingview:dd708773cf3ea:0-cea-industries-says-yzi-labs-request-to-fix-record-date-is-deficient-blocks-consent-solicitation/
Tradingview.com
  • CEA Industries' board says YZi Labs' consent-solicitation record-date request is deficient and will not be set.
  • The disclosure omissions relate to required bylaws disclosures and nominee independence concerns.
  • The company will file a consent revocation statement with the SEC and review any corrected request for compliance.
  • The filing pertains to CEA Industries Inc. and its decision on YZi Labs' consent solicitation.
  • The update comes after TradingView reported on the board's assessment of the consent-letter deficiencies.
  • The announcement notes that the request omits disclosures about share ownership and related relationships.
  • The board says these omissions prevent evaluation of potential conflicts and independence of nominees.
  • CE industries plans to file materials with the SEC and review corrected requests for compliance.
  • The report is framed as an AI-powered summary of the SEC filing and related materials.
Vote 0
0
#7
SK hynix set to prepare for US stock market listing - The Korea Times
#7 out of 8
business12h ago

SK hynix set to prepare for US stock market listing - The Korea Times

https://www.koreatimes.co.kr/business/20260325/sk-hynix-set-to-prepare-for-us-stock-market-listinghttps://www.upi.com/Top_News/World-News/2026/03/25/korea-business-SK-hynix-US-stock-listing-SEC-AI/4551774418839/https://www.koreaherald.com/article/10701954
Koreatimes.co.kr and 4 more
  • SK hynix began steps for listing on the U.S. stock market to improve access to global investors amid its AI drive, signaling a broader funding push.
  • The company filed a confidential submission with the SEC to list ADRs within the year, showing ongoing regulatory engagement.
  • Industry watchers say the listing could broaden SK hynix's funding base in overseas markets to support international expansion.
Vote 15
0
#8
finance.yahoo.com
#8 out of 8
business10h ago

Kyndryl (KD) Stock Trades Down, Here Is Why

https://finance.yahoo.com/markets/stocks/articles/kyndryl-kd-stock-trades-down-023922301.html
Finance.yahoo.com
  • Kyndryl (KD) stock fell after Morgan Stanley cut its price target and Guggenheim downgraded the stock.
  • Morgan Stanley reduced KD's price target to $13 from $28.
  • Guggenheim downgraded KD from Buy to Neutral.
  • Management departures contributed to the downgrade.
  • Kyndryl disclosed material misstatements and weak internal controls.
  • The company also disclosed an SEC document request related to cash management.
  • KD closed the day at $12.39, down 4.4% from the previous close.
  • Market reaction noted as potentially presenting buying opportunities.
  • KD has been volatile, with multiple moves of 5% or more this past year.
  • The article connects oil price trends to broader market moves affecting KD peers.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement